IMR Press / FBL / Volume 11 / Issue 1 / DOI: 10.2741/1834

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Ex vivo gene therapy: transplantation of neurotrophic factor-secreting cells for cerebral ischemia

Show Less
1 Department of Neurological Surgery, Okayama University Graduate School of Medicine and Dentistry, 2-5-1, Shikata-cho, Okayama, 700-8558, Japan
2 Department of Neurology, Medical College of Georgia, 1120, 15th street, BI-3080, Augusta, GA, 30912
3 Research and Affiliations Service Line, Augusta VA Medical Center, Augusta, GA 30912
Academic Editor:Cesario Borlongan
Front. Biosci. (Landmark Ed) 2006, 11(1), 760–775;
Published: 1 January 2006
(This article belongs to the Special Issue Gene therapy for stroke)

Expressions of various neurotrophic factors or their receptors fluctuate after stroke, which in part prompted investigations into the efficacy of neurotrophic factors as treatment modality for stroke. The methods to deliver neurotrophic factors into the brain can be categorized into: 1) the surgical route of administration, such as intracerebral, intraventricular, intra-arterial, or intravenous systemic administration and 2) the manipulation of the therapeutic molecules via ex vivo or in vivo techniques. With ex vivo method, genetically engineered cells, including the use of autologous cells, have been explored. In this review, the potent therapeutic applications of neurotrophic factors in stroke are described, with emphasis on ex vivo methods, especially transplantation of encapsulated stem cells modified with adenovirus. Neurotrophic factor delivery, combined with ex vivo method, poses as novel treatment for stroke, although additional safety and efficacy studies remain to be examined.

Back to top